Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Statin Therapy on Adaptations to Aerobic Exercise

NCT03360916
Conditions
Cardiovascular Diseases
Interventions
Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo, Exercise Program
Drug · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Atherosclerosis
Interventions
Atorvastatin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
HIV Dementia
Interventions
Atorvastatin (generic Lipitor), placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Type 1 Diabetes
Interventions
Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York
Terminated Phase 4 Interventional Results available

Effects of Atorvastatin on Myonecrosis

NCT00344019
Conditions
Coronary Disease
Interventions
Placebo Oral Tablet, Atorvastatin 80mg, Screening
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis

NCT00361283
Conditions
Inflammation
Interventions
Atorvastatin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Healthy
Interventions
Atorvastatin
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Healthy
Interventions
Atorvastatin
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 66 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

NCT03351998
Conditions
Mitochondrial Diseases
Interventions
Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo Oral Tablet
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Kansas City, Kansas • Greenville, North Carolina
Conditions
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Atorvastatin, Capecitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Gilbert, Arizona • Greeley, Colorado • Atlanta, Georgia + 2 more
Conditions
Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cancer, Relapsed Hematologic Malignancy
Interventions
Atorvastatin
Drug
Lead sponsor
Joaquina Baranda
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Fairway, Kansas